the 10th International MDM2 Workshop
Message from the Organizer

The 10th MDM2 workshop was successful. There were more than 160 participants.
We'd like to express our gratitude to all of you.
We hope that you had great time in Japan.

See you in the next p53/MDM2 meetings!

Rieko Ohki(NCCRI, Tokyo, Japan)
Koji Itahana(Duke-NUS Medical School, Singapore)
Tomoo Iwakuma(Children's Mercy Research Institute, MO, USA)

Secretariat (in English)
開催事務局 (日本語)

What's New

The program is announced.
Sponsors are announced.
Invited speakers are announced.
Abstract submission and registration ended.
Abstract submission and registration deadline extended to September 8 (17:00 Japan time).
Early registration ended. Registration will start again from July 27th, 2023 (9:30 Japan time).
Early registration period has been extended to July 25th, 2023 (9:00 Japan time).
Poster awards with a maximum prize of 50,000 yen are scheduled. Please enjoy the poster session!
A tentative program is announced.
Early registration and Abstract submission have started.
Organizing committee and International organizing committee are announced.
Website released

Early Registration deadline:
July 25th, 2023 (9:00 Japan time)

Registration re-open:
July 27th, 2023

Registration and Abstract Submission deadline:
September 8, 2023 (17:00 Japan time)

We are looking for donations and advertisements.

Welcome Message

MDM2 and its homolog MDM4 (also known as MDMX) are the two most important negative regulators of the tumor suppressor p53 by acting as an E3 ubiquitin ligase complex to promote p53 degradation and physically binding to inhibit the p53’s transcriptional functions. These proteins are overexpressed in about 30% of human cancers. Overexpression of MDM2/MDM4 not only inhibits p53 functions but also shows p53-independent oncogenic activities. Inhibitors against MDM2 and MDM4 have been developed to reactivate wild-type p53 in tumors, some of which are currently in clinical trials.

The MDM2 Workshop has been held alternately in the U.S. and Europe every two to three years to bring together the p53/MDM2 field, present the latest research, facilitate collaboration, and exchange reagents. The 10th International MDM2 Workshop will be held in Japan, for the first time in Asia. Notably, this is the first MDM2 Workshop since the COVID-19 pandemic started. The Workshop will be held at the auditorium of the National Cancer Center Research Institute (NCCRI) in Tokyo, Japan, on October 15-18, 2023.

The meeting will be co-organized by:

Rieko Ohki
Rieko Ohki
(NCCRI, Tokyo, Japan)
Koji Itahana
Koji Itahana
(Duke-NUS Medical School, Singapore)
Tomoo Iwakuma
Tomoo Iwakuma
(Children’s Mercy Research Institute, MO, USA)


On the first day of the workshop, we are planning a special symposium on MDM2 to discuss the historical discoveries on MDM2 and the future directions of MDM2 research.

This symposium offers a fascinating opportunity for many researchers to hear directly from the actual discoverers about the breakthroughs that are featured in textbooks such as "the biology of cancer.” Furthermore, on the third day, we will conduct special sessions aimed at bridging the rapidly advancing field of cancer immunology with the MDM2/MDM4/p53 field.

Day 1: October 15, 2023 (Sunday)

2:30 – 4:00pm
Registration – Lobby
4:00 – 4:10pm
Welcome and opening remarks (Rieko Ohki, Koji Itahana, Tomoo Iwakuma)
4:10 – 4:20pm
Welcome talk by Hitoshi Nakagama, National Cancer Center

Opening Session 1: Celebrating the discovery of MDM2 and its functions

Chair: Arnold Levine
4:20 – 4:50pm
S1: Donna George
Gene amplification and the discovery of MDM2
4:50 – 5:20pm
S2: Jamil Momand & Gerry Zambetti
Discovery of Mdm2 as an inhibitor of p53
5:20 – 5:55pm
S3: Guillermina Lozano
The physiological consequences of too little or too much Mdm2
5:55 – 6:10pm
6:10 – 6:40pm
S4: Binh Vu
Discovery of Nutlins
6:40 – 7:15pm
S5: Matthias Dobbelstein
MDM2/MDM4 – sensor, effector and target
7:45 –9:45pm
Welcome Party at SCHMATZ (

Day 2: October 16, 2023 (Monday)

8:30 – 8:40am
Welcome talk by Hiroyuki Mano, National Cancer Center Research Institute
8:40 – 9:15am
S6: Carol Prives (Keynote talk)
p53-independent roles of Mdm2 and MdmX in cell growth, cell death and metastasis

Session 2: Novel function and regulation of MDM2/MDM4/p53 (part 1)

9:15 – 9:40am
S7: Wei Gu
The complexity of p53-mediated tumor suppression and its regulation by Mdm2 and Mdmx
9:40 – 10:00am
S8: Dawn Chandler
Alternative splicing of MDM2: Mechanisms and therapeutic targets
10:00 – 10:20am
S9: Tomoo Iwakuma
APOBEC4, a novel target of p53, is required for MDM2 antagonist-mediated tumor suppression
10:20 – 10:35am
ST1: Alexandra Indeglia
PADI4 is a key epigenetic regulator of the p53 pathway and tumor suppression
10:35 – 11:05am

Session 3: p53-independent functions of MDM2/MDM4

11:05 – 11:25am
S10: Lindsey Mayo
The tumor suppressor pVHL represses signaling pathways that increase Mdm2
11:25 – 11:40am
ST2: Laetitia Linares
MDM2 regulates a metabolic crosstalk between liposarcoma and muscle sustains tumor growth
11:40 – 11:55am
ST3: Rasoul Pourebrahim
P53-independent role of Mdm2 in metabolic maintenance of hematopoietic stem cells via mevalonate pathway
11:55 – 12:10pm
ST4: Carla Finkielstein
Targeting of the core clock mechanism by MDM2 dictates circadian oscillations
12:10 – 2:10pm
LUNCH & Poster (1:00-2:00pm) Session – at NCCRI, Tokyo Poster presenters; please be at the poster session between 1:00-2:00pm

Special sessions: Cancer Immunology

2:10 – 2:50pm
S11: Tadatsugu Taniguchi (Keynote talk)
Interferons, p53/MDM2 and DAMPs; discovering the underpinnings of immunity

Session 4: MDM2/MDM4/p53 in immunity and tumor immunity

2:50 – 3:15pm
S12: Galina Selivanova
MDM2 inhibitors trigger p53-dependent interferon response thus promoting anti-cancer immunity
3:15 – 3:35pm
S13: Koji Itahana
The novel role of the MDM2-p53 pathway in host defense by regulating iron metabolism in macrophages
3:35 – 3:50pm
ST5: Wenwei Hu
p53 suppresses MHC-II presentation by the intestinal epithelium to protect intestinal stem cells and mucosal epithelium upon radiation
3:50 – 4:05pm
ST6: Amy Hui Ping Khor
p53 in the regulation of the innate immune response and gut microbiome
4:05 – 4:35pm

Session 5: MDM2/MDM4/p53 in tumor immunity and microenvironments, and immunotherapy

4:35 – 5:00pm
S14: Yinon Ben-Neriah
Immunity in acute myeloid leukemia: where the immune response and targeted therapy meet
5:00 – 5:25pm
S15: Luis Martinez
p53 engages the cGAS/STING pathway for tumor suppression
5:25 – 5:45pm
S16: Masanobu Oshima
Gain-of-function mutant p53 for activin signaling-induced epithelial-to-mesenchymal transition (EMT)
5:45 – 6:05pm
S17: Susumu Goyama
Targeting TP53 for acute myeloid leukemia and its relation to tumor immunity
6:05 – 6:20pm
ST7: Yong Li
Targeting missense p53 mutants using AI, antibodies, and vaccines

Day 3: October 17, 2023 (Tuesday)

8:30 – 9:05am
S18: Sir. David Lane (Keynote talk)
Design-rules for stapled peptides with on-target in vivo activity: Application to Mdm2/X antagonists

Session 6: Animal models of MDM2/MDM4/p53

9:05 – 9:30am
S19: Laura Attardi
p53 repurposes an injury repair program during lung cancer suppression
9:30 – 9:55am
S20: James Manfredi
Mdm2 regulates gene expression by p53 in vivo through both canonical and non-canonical modes of gene occupancy
9:55 – 10:10am
ST8: Shunbin Xiong
The amino terminus of Mdm4 contributes to p53 inhibition in vivo
10:10 – 10:25am
ST9: Masataka Yokoyama
Protective role of endothelial p53 in stress induced vascular malignancy
10:25 – 10:55am

Session 7: Novel function and regulation of MDM2/MDM4/p53 (part 2)

10:55 – 11:20am
S21: Jill Bargonetti
A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 to chromatin
11:20 – 11:40am
S22: Chandra Verma
Mechanisms of phosphorylations along the MDM2-MDMX-p53 axis
11:40 – 12:00pm
S23: Rieko Ohki
A novel extrinsic apoptosis pathway regulated via the p53-p53PAD7-Hippo-YAP/TAZ axis
12:00 – 12:15pm
ST10: Zhaohui Feng
The E3 ubiquitin ligase TRIM21 regulates mutant p53 accumulation and gain-of-function in cancer
12:15 – 2:15pm
LUNCH & Poster (1:00-2:00pm) Session – at NCCRI, Tokyo
Poster presenters; please be at the poster session between 1:00-2:00pm

Session 8: Controls of p53 signaling by MDM2/MDM4 and other proteins

2:15 – 2:40pm
S24: Hua Lu
Coiled-coil domain containing 3 suppresses breast cancer growth by protecting p53 from MDM2-mediated proteolytic degradation
2:40 – 3:00pm
S25: Manabu Kurokawa
An E3 ligase for Mdm2 and Mdm4
3:00 – 3:15pm
ST11: Keiko Kawauchi
Emerging roles of actin in p53-dependent DNA damage responses
3:15 – 3:30pm
ST12: Vivi Kasim
Identification and application of new regulators of MDM2-p53 complex integrity
3:30 – 3:45pm
ST13: Vanesa Olivares-Illana
The E3 ubiquitin ligase and translation factor activities of MDM2 control the expression levels of p53 and RB tumour suppressors
3:45 – 4:15pm
BREAK & Discussion – Lobby

Session 9: Functions of p53, mutant p53, p53 family, and p53 isoforms

4:15 – 4:40pm
S26: Kanaga Sabapathy
p44, the amino-terminal lacking isoform of p53, is dispensable for tumor suppression but regulates male fertility in mice
4:40 – 5:00pm
S27: Marco Candeias
Alternative translation in p53 mRNA: the switch from tumor suppressor to oncogene?
5:00 – 5:15pm
ST14: Yu Chen
Modified p53 pathway promotes the malignant progression of PanNET by activating the Akt pathway and altering metabolism
5:15 – 5:30pm
ST15: Mizuho Nakayama
Wnt signaling activation in colon cancer cells by gain-of-function mutant p53 through COX-2/PGE2 pathway
5:30 – 5:45pm
ST16: Marco Napoli
Nutlin-3a/pramlintide combination as a novel therapeutic strategy to target the p53 pathway in cancer
7:00 – 9:30pm
WORKSHOP DINNER at Berth One Tokyo (

Day 4: October 18, 2023 (Wednesday)

Session 10: Development of therapies targeting MDM2/MDM4/p53 (part1)

8:30 – 8:55am
S28: Christine Eischen
New Insights into Targeted Mdm2 Degradation
8:55 – 9:15am
S29: Takafumi Koyama
Clinical Utility and Emerging Resistance Mechanisms of Milademetane, an MDM2 Inhibitor, for MDM2-amplified Intimal Sarcoma
9:15 – 9:30am
ST17: Shruti Bhatt
Targeting non-transcriptional function of TP53 to overcome therapy resistance in leukemia
9:30 – 9:45am
ST18: Carlotta Giorgi
Innovative treatment options for cancers harboring p53 alterations by antagonizing the P2X7R
9:45 – 10:10pm
BREAK & Discussion – Lobby

Session 11: Development of therapies targeting MDM2/MDM4/p53 (part 2)

10:10 – 10:35am
S30: Jiandong Chen
Hypothermia treatment of tumors with temperature sensitive p53 mutations
10:35 – 10:50am
ST19: James A DeCaprio
Activity of MDM2 degrader KTX-049 in Merkel cell carcinoma
10:50 – 11:05am
ST20: Diana Spiegelberg
Targeting mutant p53: Evaluation of novel anti-p53R175H monoclonal antibodies as agents for molecular imaging
11:05 – 11:20am
ST21: Alejandro Parrales
Simultaneous ROS-mediated DNA damage and ATM inhibition induce p53 synthetic lethality
11:20 – 12:05pm
S31: Arnold Levine (Final Remarks)
Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent
12:05 –
Boxed LUNCH and Departure/Optional tour

1:20pm: Optional Conference Tour

1:20pm dispatch / 1:30pm departure
National Cancer Center (Tsukiji)
Imperial Palace
Sakashimon Gate - Nijubashi Bridge - Statue of Masanari Kusunoki
Walking & Shopping
Asakusa Kannon and Nakamise Shopping Street
Tokyo Sky Tree [TEMBO DECK]
View from 350m above ground
Around 7:00pm
Return to National Cancer Center (Tsukiji)


Highlighted speakers

(Alphabetized by last name)

David Lane
(Karolinska Institute, Sweden)
Arnold Levine
(Institute for Advanced Study, US)
Carol Prives
(Columbia University, US)
Tadatsugu Taniguchi
(The University of Tokyo, Japan)

Opening session keynote speakers

(Alphabetized by last name)

Matthias Dobbelstein
(University Medical Center Göttingen, Germany)
Donna George
(University of Pennsylvania, US)
Guillermina Lozano
(MD Anderson Cancer Center, US)
Jamil Momand
(California State University, Los Angeles, US)
Binh Vu
(PMV Pharmaceuticals, US)
Gerard Zambetti
(St. Jude Children’s Research Hospital, US)

Other speakers

(Alphabetized by last name)

Laura Attardi 
(Stanford University School of Medicine, US)
Jill Bargonetti
(City University of New York, US)
Yinon Ben-Neriah
(Hebrew University-Hadassah Medical School, Israel)
Marco Candeias
(Kyoto University, Japan)
Dawn Chandler 
(The Ohio State University, US)
Jiandong Chen
(Moffitt Cancer Center, US)
Christine M. Eischen 
(Thomas Jefferson University, US)
Susumu Goyama
(The University of Tokyo, Japan)
Wei Gu
(Columbia University, US)
Koji Itahana
(Duke-NUS Medical School, Singapore)
Tomoo Iwakuma
(Children's Mercy Research Institute, US)
Takafumi Koyama
(National Cancer Center Hospital, Tokyo, Japan)
Manabu Kurokawa
(Kent State University, US)
Hua Lu
(Tulane University, US)
James Manfredi
(Icahn School of Medicine at Mount Sinai, US)
Luis Martinez
(Stony Brook University, US)
Lindsey Mayo
(Indiana University School of Medicine, US)
Rieko Ohki
(National Cancer Center Research Institute, Japan)
Masanobu Oshima
(Kanazawa University, Japan)
Kanaga Sabapathy
(National Cancer Center Singapore, Singapore)
Galina Selivanova
(Karolinska Institutet, Sweden)
Chandra Verma 
(A*STAR Bioinformatics Institute, Singapore)


Kindly process payment with your credit card (corporate or personal card).
Be advised, however, that debit cards or any other prepaid cards are not accepted on our payment processing system.
Thank you very much in advance for your kind understanding.

Early Registration (Before July 10th)

Academia or Non-Profit Institute Corporate
Full Conference with welcome party and
conference dinner
Faculty JPY
Trainees JPY
Corporate JPY
One-day registration (first day only) with
welcome party
Faculty JPY
Trainees JPY
Corporate JPY

Registration(Open from July 13th, Deadline August 21th)

Academia or Non-Profit Institute Corporate
Full Conference with welcome party and
conference dinner
Faculty JPY
Trainees JPY
Corporate JPY
One-day registration (first day only) with
welcome party
Faculty JPY
Trainees JPY
Corporate JPY
●Please note that onsite registration and payment will not be available

non-invited participants

Invited registration

committee members
invited speakers

Abstract submission


The hotels listed below are located within the 10-minute walk distance from the workshop venue.

  • The KEIKYU EX INN Higashiginza
  • APA Hotel Tsukiji-Eki Minami
  • Sotetsu Fresa Inn Ginza-Nanachome
  • TOKYU STAY Tsukiji
  • TOKYU STAY Ginza
  • Mitsui Garden Hotel Ginza-gochome

You can contact the hotel directly or your travel agancy to make a reservation for yourself.

There are also other hotels near the venue listed below.
You can visit the hotel website and make a reservation by yourself.

Conference coordinator
Rieko Ohki
Secretariat (in English)
開催事務局 (日本語)

Restaurant information can be found in the following link:


The workshop will be held in the auditorium of the National Cancer Center Research Institute (NCCRI) in Tokyo, Japan.

Directions to the NCCRI

Map of the NCCRI campus



National Cancer Center Research Institute (NCCRI), Tokyo, Japan


Rieko Ohki
National Cancer Center Research Institute
Koji Itahana
Duke-NUS Medical School, Singapore
Tomoo Iwakuma
Children's Mercy Research Institute, USA


Hiroyuki Mano

National Cancer Center Research Institute
Hitoshi Nakagama

National Cancer Center
Masanobu Oshima
Kanazawa University
Tomoaki Tanaka
Chiba University
Koichi Matsuda
The University of Tokyo
Koji Okamoto
Teikyo University
Hirofumi Arakawa
National Cancer Center Research Institute
Takashi Tokino
Sapporo Medical School
Manabu Kurokawa
Kent State University
Koichi Kawahara
Kagoshima University
Marco Candeias
Kyoto University
Chizu Tanikawa
The University of Tokyo



Arnold Levine
Institute for Advanced Study, US
David Lane
Karolinska Institute, Sweden
Carol Prives
Columbia University, US
Guillermina Lozano
MD Anderson Cancer Center, US
Karen Vousden
The Francis Crick Institute, UK
Wei Gu
Columbia University, US
James Manfredi
Icahn School of Medicine at Mount Sinai, US
Laura Attardi
Stanford University School of Medicine, US
Ygal Haupt
Peter MacCallum Cancer Center, Australia
Yanping Zhang
University of North Carolina at Chapel Hill, US
Hua Lu
Tulane University, US
Jiandong Chen
Moffitt Cancer Center, US
Christine Eischen
Thomas Jefferson University, US
Ute Moll
Stony Brook University, US
Matthias Dobbelstein
University Medical Center Göttingen, Germany
Pierre Hainaut
Institute for Advanced Biosciences, France



Please email us any inquiries about the conference, registration, and special accessibility needs.

Conference coordinator
Rieko Ohki
Secretariat (in English)
開催事務局 (日本語)